[go: up one dir, main page]

MA34058B1 - Formes de rifaximine, et leurs utilisations - Google Patents

Formes de rifaximine, et leurs utilisations

Info

Publication number
MA34058B1
MA34058B1 MA35196A MA35196A MA34058B1 MA 34058 B1 MA34058 B1 MA 34058B1 MA 35196 A MA35196 A MA 35196A MA 35196 A MA35196 A MA 35196A MA 34058 B1 MA34058 B1 MA 34058B1
Authority
MA
Morocco
Prior art keywords
forms
rifaximine
pharmaceutical
rifaximin
relates
Prior art date
Application number
MA35196A
Other languages
Arabic (ar)
English (en)
Inventor
Karen S Gushurst
Donglai Yang
Petinka Vlahova
Jeffrey S Stults
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MA34058B1 publication Critical patent/MA34058B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des formes polymorphiques de rifaximine, leur utilisation dans des préparations médicamenteuses, et des traitements thérapeutiques les utilisant.
MA35196A 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations MA34058B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/708,836 US8486956B2 (en) 2008-02-25 2010-02-19 Forms of rifaximin and uses thereof
PCT/US2011/024981 WO2011103120A1 (fr) 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34058B1 true MA34058B1 (fr) 2013-03-05

Family

ID=44483273

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35196A MA34058B1 (fr) 2010-02-19 2011-02-16 Formes de rifaximine, et leurs utilisations

Country Status (21)

Country Link
US (5) US8486956B2 (fr)
EP (1) EP2536734B1 (fr)
JP (2) JP2013520427A (fr)
KR (1) KR20120140244A (fr)
CN (2) CN102834398A (fr)
AU (3) AU2011218258B2 (fr)
BR (1) BR112012020863A2 (fr)
CA (1) CA2790332A1 (fr)
CR (1) CR20120449A (fr)
EA (1) EA201270722A1 (fr)
GE (2) GEP20156230B (fr)
IL (1) IL221299A (fr)
MA (1) MA34058B1 (fr)
MX (1) MX353827B (fr)
MY (1) MY158992A (fr)
NZ (1) NZ601670A (fr)
PH (1) PH12012501623A1 (fr)
SG (1) SG183188A1 (fr)
TN (1) TN2012000414A1 (fr)
WO (1) WO2011103120A1 (fr)
ZA (1) ZA201206227B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3001996A (en) * 1957-02-08 1961-09-26 Hans S Mannheimer Sulfates and sulfonates of n-tertiary amino alkyl-carboxylic acid amides
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP2257557A4 (fr) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd Formes de rifaximine et utilisations correspondantes
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
GEAP202112996A (en) * 2010-07-12 2021-09-10 Salix Pharmaceuticals Ltd Us Formulations of rifaximin and uses thereof
BR112013005772A2 (pt) * 2010-09-13 2019-09-24 Cipla Ltd composição compreendendo rifaximina na forma de pertículas, composição farmacêutica, uso de uma composição, método para tratar uma infecção bacteriana e processo para preparar uma composição farmacêutica
KR20140026379A (ko) * 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
CA2834829A1 (fr) * 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Solvate de dimethylformamide rifaximine
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ES2986825T3 (es) 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (fr) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CA2908525C (fr) 2013-04-12 2021-04-06 Alfa Wassermann S.P.A. Administration d'ains, compositions, procedes et systemes associes
CN103509038B (zh) * 2013-09-30 2016-01-20 浙江思贤制药有限公司 一种新晶型利福昔明ζ及其制备方法
EP2927235B1 (fr) 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
MX375805B (es) 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
WO2016204474A2 (fr) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 Composition vétérinaire pour le traitement de l'entérite chez les animaux contenant des formes cristallines de rifaximine
EP3518924B1 (fr) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Formes de dispersions solides de rifaximine
CN117447487A (zh) * 2022-07-19 2024-01-26 重庆圣华曦药业股份有限公司 一种利福昔明的纯化方法及其在利福昔明片剂中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA2396079A1 (fr) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
DE102004004433A1 (de) 2004-01-28 2005-08-18 Trützschler GmbH & Co KG Vorrichtung an einer Spinnereimaschine, insbesondere Karde, Reiniger o. dgl., zum Aufziehen einer Garnitur auf eine Walze
US7226931B2 (en) 2004-07-22 2007-06-05 Cumbre Pharmaceuticals Inc. (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2069363B1 (fr) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximine sous une forme amorphe
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
MY144578A (en) * 2007-07-27 2011-10-14 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (fr) 2007-10-10 2009-04-16 Lupin Limited Combinaisons thérapeutiques et compositions pour le traitement de troubles gastro-intestinaux
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
EP2257557A4 (fr) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd Formes de rifaximine et utilisations correspondantes
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US20100209495A1 (en) 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
KR20200100215A (ko) 2009-10-27 2020-08-25 루핀 리미티드 리팍시민의 고형 분산물
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
KR20140026379A (ko) * 2011-02-11 2014-03-05 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도

Also Published As

Publication number Publication date
SG183188A1 (en) 2012-09-27
CA2790332A1 (fr) 2011-08-25
MX353827B (es) 2018-01-31
JP2016094416A (ja) 2016-05-26
AU2011218258A1 (en) 2012-08-30
NZ601670A (en) 2014-11-28
MX2012009576A (es) 2012-12-05
TN2012000414A1 (en) 2014-01-30
AU2016269529B2 (en) 2018-06-07
AU2016269529A1 (en) 2017-01-05
JP2013520427A (ja) 2013-06-06
KR20120140244A (ko) 2012-12-28
EP2536734A4 (fr) 2013-06-26
IL221299A0 (en) 2012-10-31
ZA201206227B (en) 2018-12-19
MY158992A (en) 2016-11-30
EP2536734B1 (fr) 2016-08-31
PH12012501623A1 (en) 2012-10-22
AU2014246594B2 (en) 2016-09-15
AU2011218258B2 (en) 2015-11-05
GEP201706745B (en) 2017-10-10
US9273066B2 (en) 2016-03-01
US8569326B2 (en) 2013-10-29
IL221299A (en) 2017-11-30
US20120316334A1 (en) 2012-12-13
EA201270722A1 (ru) 2013-03-29
US9546183B2 (en) 2017-01-17
BR112012020863A2 (pt) 2016-06-21
US20140179916A1 (en) 2014-06-26
EP2536734A1 (fr) 2012-12-26
US8486956B2 (en) 2013-07-16
HK1179608A1 (zh) 2013-10-04
CN102834398A (zh) 2012-12-19
GEP20156230B (en) 2015-01-26
WO2011103120A1 (fr) 2011-08-25
US20140141081A1 (en) 2014-05-22
CN105254647A (zh) 2016-01-20
AU2014246594A1 (en) 2014-10-30
US9034892B2 (en) 2015-05-19
CR20120449A (es) 2012-11-29
US20160200738A1 (en) 2016-07-14
US20100174064A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
HUS2200034I1 (hu) Glikokonjugációs eljárások és kompozíciók
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
BR112015008245A2 (pt) composições poliméricas de tratamento.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
DK2723615T3 (da) Ulykkesbekæmpelsessystem og køretøj, der indbefatter ulykkesbekæmpelsessystemet
EA201290642A1 (ru) Соединения и способы
EP2844637A4 (fr) Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
IN2012DN06714A (fr)
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BR112013016037A2 (pt) composição em gel.
EP2654422A4 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
FR2993565B1 (fr) Composes fluorescents de type thienyldipyrromethene bores et leurs utilisations.
IN2014DN08481A (fr)
UY34817A (es) Tienopirimidinas
EP2918681A4 (fr) Gène de la fertilité et utilisations associées
EA201590962A1 (ru) Новые соединения
EP2672970A4 (fr) Formes de rifaximine et leurs utilisations
BR112013012450A2 (pt) composições, métodos de detecção e kits
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
EP2691396A4 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
EP2926712A4 (fr) Système d'insufflation
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112015005627A2 (pt) composto, composição farmacêutica, uso de composto, método de tratamento e invenção.